The following is a summary of the Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Pulmonx reported a total worldwide revenue of $20.4 million for Q3, up 15%

• U.S. revenue grew by 17% year-over-year, while international revenue increased by 12%

• Gross margin maintained at 74%, despite changes in geographic mix

• Reduced net loss to $14.1 million from $14.9 million in the same quarter last year

Business Progress:

• Implemented strategic commercial pillars leading to 280 active Zephyr Valve accounts across the U.S

• Launched LungTraX Platform pilot, a diagnostic tool aimed at streamlining patient workflows and identifying eligible patients

• Expanded international operations, particularly through new distributor relationships in China and ongoing European engagements

• Advanced clinical trials for AeriSeal system with promising data, supporting future commercial availability

Opportunities:

• The international revenue growth, particularly with contributions from a new distributor in China, indicates expanding global market presence

• Potential growth opportunities from the LungTraX platform once fully deployed in customer centers

Risks:

• Seasonality impacts observed in Q3, could pose risks if similar patterns affect future quarters

• Integration and adoption delays for LungTraX Platform could affect expected benefits and revenue from this technology

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.